Would you offer anti-HER2 therapy to a patient found to have heterogenous HER2+ residual disease after original treatment for TNBC using the Keynote522 regimen?  

63y/o F who was originally diagnosed with cT2N0 TNBC , completed KN522 regimen ->ypT1cN0, markers from her surgical path showed ER0PR0 HER2 2+ and positive via FISH in 5% of total tumor population. Original plan was to continue keytruda x 9cycles. 



Answer from: Medical Oncologist at Academic Institution
Comments
Medical Oncologist at Joliet Oncology Hematology Associates
Would you give this in addition to Keytruda?
Medical Oncologist at Onc San Antonio
Keytruda should be continued as adjuvant per KN522...
Medical Oncologist at H Lee Moffitt Cancer Center, University of South Florida
We have given these drugs in combination with pemb...
Sign in or Register to read more